ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates

ADC Therapeutics reported a quarterly loss of $0.21 per share, wider than the Zacks Consensus Estimate for a $0.19 loss but improved from a $0.36 loss a year ago. The result is a modest earnings miss, partially offset by year-over-year loss improvement, making the update mildly negative overall. The news is likely to have limited-to-moderate impact on the stock.

Analysis

ADC Therapeutics reported a quarterly loss of $0.21 per share, wider than the Zacks Consensus Estimate for a $0.19 loss but improved from a $0.36 loss a year ago. The result is a modest earnings miss, partially offset by year-over-year loss improvement, making the update mildly negative overall. The news is likely to have limited-to-moderate impact on the stock.